Table 1.
Previous reports of tocilizumab for the treatment of MKD.
| Shendi et al. (n = 1) [19] | Stoffels et al. (n = 2) [15] | Lane et al. (n = 2) [20] | Muster et al. (n = 1) [21] | |||
|---|---|---|---|---|---|---|
| Patient | 1 | 2 | 3 | 4 | 5 | 6 |
|
| ||||||
| TOC dose (mg/kg) and route of administration | 7 IV | 8 IV | 8 IV | 8 IV | 8 IV | 8 IV |
|
| ||||||
| Frequency of administration (weeks) | 4 | 4 | 4 | 4 | 4 | 4 |
|
| ||||||
| Age (range), years at onset of TOC | 13 | Not described | Not described | 24 | 13 | 36 |
|
| ||||||
| Treatment prior to TOC | COL | ANA | ANA | ANA | ETA | NSAID |
| PRED | ETA | SIMVA | ||||
| ETA | ANA | |||||
| ANA | ||||||
|
| ||||||
| Duration of treatment (months) | 20 | 5 | 5 | 24 | 13 | 48–60 |
|
| ||||||
| Outcome | ||||||
| Clinical | CR | CR | CR | CR | PR | |
| Serological | CR | Not described | PR | CR | — | |
|
| ||||||
| Adverse events | URTI | Not described | Not described | Not described | Not described | |
|
| ||||||
| Comments | CR at dose of 8 mg/kg but due to adverse events dose reduced, ultimately with stable clinical and serological status on 7 mg/kg IV every 4 weeks | — | — | MKD complicated by AA amyloidosis. Remained on therapy with PRED 0.5 mg/kg/day | Stabilized on monotherapy with TOC | After starting TOC, average hospital admissions dropped 11/yr to 3/yr |
| TOC given in combination with IVMP for first 3 yrs then as monotherapy | ||||||
IV: intravenous; COL: colchicine; PRED: prednisolone; ETA: etanercept; ANA: anakinra; NSAID: nonsteroidal anti-inflammatory drug; SIMVA: simvastatin; CR: complete response; PR: partial response; URTI: upper respiratory tract infection; TOC: tocilizumab; yrs: years.